Elisa Minenza

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

Lucio Crinò, Giuseppe Bronte, Paolo Bidoli et al. · Lung Cancer · 2019 · 156 citations

Medicine, Oncology, Metastasis +11

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Mark A. Socinski, Ben Creelan, Leora Horn et al. · Annals of Oncology · 2016 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Stefania Gori, Angelo Sidoni, Mariantonietta Colozza et al. · Annals of Oncology · 2009 · 73 citations

Medicine, Cancer Biology, Oncology +16